Sirnaomics
Sirnaomics is a leading biopharmaceutical company focused on discovery and development of RNAi therapeutics for cancer, fibrotic diseases, and other high unmet medical needs. With a strong portfolio of intellectual property and a broad pipeline, the company leverages innovative RNA interference technology, delivery platforms, and a global vision to develop novel therapeutics aimed at alleviating human suffering and advancing patient care.
Industries
Nr. of Employees
medium (51-250)
Sirnaomics
Gaithersburg, Maryland, United States, North America
Products
Dual‑targeting siRNA therapeutic for cutaneous and fibrotic indications (lead clinical candidate)
siRNA candidate designed to simultaneously reduce expression of two pro‑fibrotic/pro‑tumorigenic genes; formulated for intralesional and systemic administration and progressed through Phase I/II clinical studies.
Systemic siRNA therapeutic candidate for solid tumors (IV formulation)
Systemically administered siRNA candidate formulated with peptide copolymer carriers for intravenous delivery to solid tumors; evaluated in preclinical models and advanced into Phase I studies.
GalNAc-based liver‑targeted siRNA programs
Liver‑directed siRNA development programs using GalNAc conjugation for targeted hepatocyte delivery, applied to cardiovascular and coagulation indications in clinical studies.
mRNA vaccine and therapeutic candidates using PLNP and AI design
mRNA vaccine and therapeutic development combining polypeptide‑lipid nanoparticle delivery and AI epitope prediction methods to select antigens and design mRNA constructs.
Dual‑targeting siRNA therapeutic for cutaneous and fibrotic indications (lead clinical candidate)
siRNA candidate designed to simultaneously reduce expression of two pro‑fibrotic/pro‑tumorigenic genes; formulated for intralesional and systemic administration and progressed through Phase I/II clinical studies.
Systemic siRNA therapeutic candidate for solid tumors (IV formulation)
Systemically administered siRNA candidate formulated with peptide copolymer carriers for intravenous delivery to solid tumors; evaluated in preclinical models and advanced into Phase I studies.
GalNAc-based liver‑targeted siRNA programs
Liver‑directed siRNA development programs using GalNAc conjugation for targeted hepatocyte delivery, applied to cardiovascular and coagulation indications in clinical studies.
mRNA vaccine and therapeutic candidates using PLNP and AI design
mRNA vaccine and therapeutic development combining polypeptide‑lipid nanoparticle delivery and AI epitope prediction methods to select antigens and design mRNA constructs.
Services
Clinical development and trial support
Design and conduct of early-phase clinical trials (IND filings, Phase I/II designs, dose escalation/expansion, intralesional and IV administration).
Delivery technology licensing
Licensing of nanoparticle delivery platforms (polypeptide and polypeptide‑lipid systems) and transfer of related formulation know‑how.
Preclinical efficacy and IND‑enabling studies
In vivo efficacy testing in rodent xenograft and disease models and safety studies including non‑human primates to support IND submissions.
GMP manufacturing know‑how and process development
Guidance and execution for scalable GMP manufacturing of oligonucleotide and nanoparticle formulations for clinical supply.
Clinical development and trial support
Design and conduct of early-phase clinical trials (IND filings, Phase I/II designs, dose escalation/expansion, intralesional and IV administration).
Delivery technology licensing
Licensing of nanoparticle delivery platforms (polypeptide and polypeptide‑lipid systems) and transfer of related formulation know‑how.
Preclinical efficacy and IND‑enabling studies
In vivo efficacy testing in rodent xenograft and disease models and safety studies including non‑human primates to support IND submissions.
GMP manufacturing know‑how and process development
Guidance and execution for scalable GMP manufacturing of oligonucleotide and nanoparticle formulations for clinical supply.
Expertise Areas
- RNAi therapeutic discovery and development
- Oligonucleotide delivery platform development
- Preclinical in vivo efficacy and IND‑enabling studies
- Clinical trial design and early‑phase execution
Key Technologies
- RNA interference (siRNA)
- Polypeptide nanoparticle delivery
- Histidine‑lysine copolymer peptide carriers
- GalNAc liver‑targeting chemistry